Toggle navigation
Search
Tree View
MeSH on Demand
MeSH 2024
About
Suggestions
Contact Us
Adalimumab
MeSH Descriptor Data 2025
Details
Qualifiers
MeSH Tree Structures
Concepts
MeSH Heading
Adalimumab
Tree Number(s)
D12.776.124.486.485.114.224.060.250
D12.776.124.790.651.114.224.060.250
D12.776.377.715.548.114.224.200.250
Unique ID
D000068879
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000068879
Scope Note
A humanized monoclonal antibody that binds specifically to
TNF-ALPHA
and blocks its interaction with endogenous
TNF RECEPTORS
to modulate
INFLAMMATION
. It is used in the treatment of
RHEUMATOID ARTHRITIS
;
PSORIATIC ARTHRITIS
;
CROHN'S DISEASE
and
ULCERATIVE COLITIS
.
Entry Term(s)
Adalimumab-adbm
Adalimumab-atto
Amjevita
Cyltezo
D2E7 Antibody
Humira
Pharm Action
Antirheumatic Agents
Tumor Necrosis Factor Inhibitors
See Also
Tumor Necrosis Factor-alpha
Public MeSH Note
2016; ADALIMUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2002-2015
History Note
2016 (2002)
Date Established
2016/01/01
Date of Entry
2015/07/01
Revision Date
2021/07/01
Allowable Qualifiers
administration & dosage (AD)
adverse effects (AE)
analysis (AN)
biosynthesis (BI)
blood (BL)
cerebrospinal fluid (CF)
chemistry (CH)
classification (CL)
drug effects (DE)
economics (EC)
genetics (GE)
history (HI)
immunology (IM)
isolation & purification (IP)
metabolism (ME)
pharmacokinetics (PK)
pharmacology (PD)
physiology (PH)
poisoning (PO)
radiation effects (RE)
therapeutic use (TU)
toxicity (TO)
ultrastructure (UL)
urine (UR)
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Monoclonal [D12.776.124.486.485.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
Abciximab [D12.776.124.486.485.114.224.060.125]
Adalimumab [D12.776.124.486.485.114.224.060.250]
Alemtuzumab [D12.776.124.486.485.114.224.060.313]
Basiliximab [D12.776.124.486.485.114.224.060.344]
Bevacizumab [D12.776.124.486.485.114.224.060.375]
Brentuximab Vedotin [D12.776.124.486.485.114.224.060.438]
Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
Cetuximab [D12.776.124.486.485.114.224.060.750]
Daclizumab [D12.776.124.486.485.114.224.060.766]
Denosumab [D12.776.124.486.485.114.224.060.782]
Gemtuzumab [D12.776.124.486.485.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.486.485.114.224.060.794]
Ipilimumab [D12.776.124.486.485.114.224.060.798]
Natalizumab [D12.776.124.486.485.114.224.060.813]
Nivolumab [D12.776.124.486.485.114.224.060.829]
Omalizumab [D12.776.124.486.485.114.224.060.844]
Palivizumab [D12.776.124.486.485.114.224.060.860]
Panitumumab [D12.776.124.486.485.114.224.060.864]
Ramucirumab [D12.776.124.486.485.114.224.060.866]
Ranibizumab [D12.776.124.486.485.114.224.060.868]
Trastuzumab [D12.776.124.486.485.114.224.060.875]
Ustekinumab [D12.776.124.486.485.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Monoclonal [D12.776.124.790.651.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
Abciximab [D12.776.124.790.651.114.224.060.125]
Adalimumab [D12.776.124.790.651.114.224.060.250]
Alemtuzumab [D12.776.124.790.651.114.224.060.375]
Basiliximab [D12.776.124.790.651.114.224.060.407]
Bevacizumab [D12.776.124.790.651.114.224.060.438]
Brentuximab Vedotin [D12.776.124.790.651.114.224.060.469]
Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
Cetuximab [D12.776.124.790.651.114.224.060.750]
Daclizumab [D12.776.124.790.651.114.224.060.766]
Denosumab [D12.776.124.790.651.114.224.060.782]
Gemtuzumab [D12.776.124.790.651.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.790.651.114.224.060.794]
Ipilimumab [D12.776.124.790.651.114.224.060.798]
Natalizumab [D12.776.124.790.651.114.224.060.813]
Nivolumab [D12.776.124.790.651.114.224.060.829]
Omalizumab [D12.776.124.790.651.114.224.060.844]
Palivizumab [D12.776.124.790.651.114.224.060.860]
Panitumumab [D12.776.124.790.651.114.224.060.864]
Ramucirumab [D12.776.124.790.651.114.224.060.866]
Ranibizumab [D12.776.124.790.651.114.224.060.868]
Trastuzumab [D12.776.124.790.651.114.224.060.875]
Ustekinumab [D12.776.124.790.651.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Monoclonal [D12.776.377.715.548.114.224]
Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Abciximab [D12.776.377.715.548.114.224.200.125]
Adalimumab [D12.776.377.715.548.114.224.200.250]
Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Basiliximab [D12.776.377.715.548.114.224.200.407]
Bevacizumab [D12.776.377.715.548.114.224.200.438]
Brentuximab Vedotin [D12.776.377.715.548.114.224.200.469]
Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
Cetuximab [D12.776.377.715.548.114.224.200.750]
Daclizumab [D12.776.377.715.548.114.224.200.766]
Denosumab [D12.776.377.715.548.114.224.200.782]
Gemtuzumab [D12.776.377.715.548.114.224.200.790]
Inotuzumab Ozogamicin [D12.776.377.715.548.114.224.200.794]
Ipilimumab [D12.776.377.715.548.114.224.200.798]
Natalizumab [D12.776.377.715.548.114.224.200.813]
Nivolumab [D12.776.377.715.548.114.224.200.829]
Omalizumab [D12.776.377.715.548.114.224.200.844]
Palivizumab [D12.776.377.715.548.114.224.200.860]
Panitumumab [D12.776.377.715.548.114.224.200.864]
Ramucirumab [D12.776.377.715.548.114.224.200.866]
Ranibizumab [D12.776.377.715.548.114.224.200.868]
Trastuzumab [D12.776.377.715.548.114.224.200.875]
Ustekinumab [D12.776.377.715.548.114.224.200.937]
Expand All
Collapse All
Adalimumab
Preferred
Concept UI
M0422769
Scope Note
A humanized monoclonal antibody that binds specifically to
TNF-ALPHA
and blocks its interaction with endogenous
TNF RECEPTORS
to modulate
INFLAMMATION
. It is used in the treatment of
RHEUMATOID ARTHRITIS
;
PSORIATIC ARTHRITIS
;
CROHN'S DISEASE
and
ULCERATIVE COLITIS
.
Terms
Adalimumab
Preferred Term
Term UI
T000877628
Date
03/30/2015
LexicalTag
NON
ThesaurusID
Humira
Narrower
Concept UI
M0444260
Terms
Humira
Preferred Term
Term UI
T529546
Date
01/02/2003
LexicalTag
TRD
ThesaurusID
US
Amjevita
Narrower
Concept UI
M000638102
Terms
Amjevita
Preferred Term
Term UI
T000934806
Date
10/17/2017
LexicalTag
TRD
ThesaurusID
NLM (2019)
Cyltezo
Narrower
Concept UI
M000638106
Terms
Cyltezo
Preferred Term
Term UI
T000934814
Date
10/17/2017
LexicalTag
TRD
ThesaurusID
NLM (2019)
D2E7 Antibody
Narrower
Concept UI
M000638385
Terms
D2E7 Antibody
Preferred Term
Term UI
T000877629
Date
03/30/2015
LexicalTag
LAB
ThesaurusID
NLM (2002)
Adalimumab-atto
Narrower
Concept UI
M000638621
Terms
Adalimumab-atto
Preferred Term
Term UI
T000934807
Date
10/17/2017
LexicalTag
NON
ThesaurusID
NLM (2019)
Adalimumab-adbm
Narrower
Concept UI
M000638622
Terms
Adalimumab-adbm
Preferred Term
Term UI
T000934815
Date
10/17/2017
LexicalTag
NON
ThesaurusID
NLM (2019)
page delivered in 0.13s
